Ontology highlight
ABSTRACT:
SUBMITTER: Fukuhara T
PROVIDER: S-EPMC10526408 | biostudies-literature | 2023 Sep
REPOSITORIES: biostudies-literature
Fukuhara Tatsuro T Imai Kazuhiro K Nakagawa Taku T Igusa Ryotaro R Yokota Hayato H Watanabe Kana K Suzuki Aya A Morita Mami M Onodera Ren R Inoue Akira A Miura Masatomo M Minamiya Yoshihiro Y Maemondo Makoto M
Biomedicines 20230910 9
Osimertinib is a standard treatment for patients with EGFR-mutated non-small cell lung carcinoma (NSCLC). We evaluated the relationship between plasma osimertinib concentrations and treatment outcome in patients with NSCLC for this cohort study. The plasma levels of osimertinib and its metabolite AZ5104 were measured a week after the start of treatment (P1). The primary endpoint was to evaluate the correlation between plasma concentration and adverse events (AEs). The correlation with treatment ...[more]